PULSAR in Systemic Therapy for Pancreatic Cancer

Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection. A substantial proportion of patients present with locally advanced, unresectable disease at the time of diagnosis, making intensive systemic therapy the current standard of care. For selected patients, radiation therapy (RT) is integrated to improve local control. Local progression in the pancreas can lead to severe complications, including intractable pain, gastric outlet obstruction, and biliary obstruction, which ultimately

Trial Details

NCT ID
NCT07269626
Phase
PHASE2
Sponsor
Samsung Medical Center
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Personalized Ultrafractionated Adaptive Radiotherapy
Locations (sample)
  • Seoul, Select Province/State, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Age ≥ 19 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Histologically confirmed pancreatic ductal adenocarcinoma.
  • Disease extent classified as borderline resectable, locally advanced, or oligometastatic disease (defined as ≤ 3 metastatic lesions) at the time of…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →